The multifunctional nature of Alzheimer's disease calls for MTDLs (multitarget-directed ligands) to act on different components of the pathology, like the cholinergic dysfunction and amyloid aggregation. Such MTDLs are usually on the basis of cholinesterase inhibitors (e.g. tacrine or huprine) coupled with another active molecule aimed at a different target. To aid in the design of these MTDLs, we report the crystal structures of hAChE (human acetylcholinesterase) in complex with FAS-2 (fasciculin 2) and a hydroxylated derivative of huprine (huprine W), and of hBChE (human butyrylcholinesterase) in complex with tacrine. Huprine W in hAChE and tacrine in hBChE reside in strikingly similar positions highlighting the conservation of key interactions, namely, π-π/cation-π interactions with Trp 86 (Trp 82 ), and hydrogen bonding with the main chain carbonyl of the catalytic histidine residue. Huprine W forms additional interactions with hAChE, which explains its superior affinity: the isoquinoline moiety is associated with a group of aromatic residues (Tyr 337 , Phe 338 and Phe 295 not present in hBChE) in addition to Trp 86 ; the hydroxyl group is hydrogen bonded to both the catalytic serine residue and residues in the oxyanion hole; and the chlorine substituent is nested in a hydrophobic pocket interacting strongly with Trp 439 . There is no pocket in hBChE that is able to accommodate the chlorine substituent.
INTRODUCTION
AD (Alzheimer's disease), which is the most common cause of senile dementia, is a major public health issue with devastating economic and human impacts. As of 2011, the estimated number of patients needing treatment is 7-8 million in Europe and 4-5 million in the U.S.A., with a total of 24 million worldwide. Considering the aging of the world's population, the situation is expected to worsen, with the predicted burden of AD victims reaching 42 million by 2020 [1] .
AD results from a neurodegenerative process occurring in the central nervous system. It is clinically characterized by a loss of memory and cognition that is associated with deterioration of the basal forebrain cholinergic neuronal network, resulting in a reduction in the level of the neurotransmitter acetylcholine [2] . AD is histologically characterized by aberrant proteinaceous deposits: (i) from Aβ (β-amyloid) peptide outside neurons; and (ii) from microtubule-associated Tau protein inside neurons. The aetiology of AD is not completely understood, yet it is clearly complex and multifactorial. Although several treatment strategies have been proposed [3, 4] , most current therapeutic options involve restoring acetylcholine levels in the brain. hAChE [human AChE (acetylcholinesterase)] inhibitors donepezil (Aricept ® ), rivastigmine (Exelon ® ) and galanthamine (Reminyl ® ) are currently approved anti-AD drugs [5] . In previous studies, BChE (butyrylcholinesterase) received attention owing to its role in modulating acetylcholine levels in cholinergic neurons under normal conditions [6] and when AChE activity decreases [7, 8] . Consequently, both enzymes are important targets in AD treatment [9] [10] [11] .
The complex aetiology of AD has prompted the development of MTDLs (multitarget-directed ligands) that act simultaneously on different components of AD pathology, e.g. hAChE and amyloid. Inhibitors of hAChE have been used as scaffolds to synthesize such MTDLs [12] [13] [14] [15] .
Rational design of more potent hAChE and hBChE (human BChE) inhibitors would benefit from a better understanding of how the current inhibitors bind to the active sites of these enzymes. Structural data on hAChE in complex with anti-AD drugs have been available only recently and have shown how important it is to analyse complexes formed with the human enzyme rather than with AChE from other species [16] . Yet, 3D structures of AChE in complex with inhibitors suitable for the design of MTDLs are available currently only for mAChE (mouse AChE) and TcAChE (Torpedo californica AChE) [17] [18] [19] . There is no structural information on hBChE in complex with suitable inhibitors. In the present paper, we describe the crystal structures of hAChE in complex with FAS-2 (fasciculin 2) and huprine W and hBChE bound to tacrine (see Figure 1 for the structures of these inhibitors). The stabilizing effect of FAS-2 was required to Abbreviations used: AChE, acetylcholinesterase; AD, Alzheimer's disease; BChE, butyrylcholinesterase; CHO, Chinese-hamster ovary; DmAChE, Drosophila melanogaster AChE; ESRF, European Synchrotron Radiation Facility; FAS-2, fasciculin 2; hAChE, human AChE; hBChE, human BChE; mAChE, mouse AChE; MTDL, multitarget-directed ligand; PRAD, proline-rich attachment domain; TcAChE, Torpedo californica acetylcholinesterase; WAT, tryptophan amphiphilic tetramerization. 1 To whom correspondence should be addressed (email florian@nachon.net).
The atomic co-ordinates and structure factors for the structures of hAChE in complex with huprine W and FAS-2, and hBChE in complex with tacrine, have been deposited in the PDB under accession codes 4BDT and 4BDS respectively. Tacrine and huprine W are both used in the present study to create complexes with cholinesterases for X-ray crystallography. Huprine triazole is described in the Discussion section.
obtain crystals of our preparation of full-length hAChE [20] . Both of these structurally related ligands are suitable for the design of MTDLs, and their complex formed with human cholinesterases provide information that can be used in the design of inhibitors specific to each enzyme.
EXPERIMENTAL

Chemicals
Huprine W was synthesized as a racemic mixture [21] . FAS-2 from Bungarus venom was purchased from Latoxan. All other chemicals including tacrine were purchased from Sigma-Aldrich.
Recombinant hAChE and hBChE
The synthetic gene (GeneArt) coding for the full cDNA of hAChE was inserted into a pGS vector carrying the glutamine synthetase gene marker and expressed in CHO (Chinese-hamster ovary)-K1 cells. The cells were maintained in serum-free Ultraculture Medium (BioWhittaker) and transfected using jetPEI following the recommendations of the supplier (Polyplus). Transfected clones were selected by incubation in medium containing methionine sulfoximine. The enzymes, secreted into the culture medium, were purified by affinity chromatography and ionexchange chromatography as described previously [20] .
Recombinant hBChE (L530stop) is a truncated monomer containing residues 1-529, but is missing 45 C-terminal residues that include the tetramerization domain. Four of the nine carbohydrate attachment sites were deleted by site-directed mutagenesis. Mutagenesis of Asn 486 resulted in glycosylation of Asn 485 , an asparagine that is not glycosylated in native hBChE, so that the recombinant hBChE contains six N-linked glycans [22] The recombinant hBChE gene was expressed in CHO-K1 cells, secreted into serum-free culture medium, and purified by affinity and ion-exchange chromatographies as described previously [22] .
The enzymes were concentrated to 14 mg/ml (hAChE) or 7 mg/ml (hBChE) using a Centricon-30 ultrafiltration microconcentrator (30000 molecular mass cut-off, Amicon, Millipore) in 10 mM Mes buffer, pH 6.5. The enzyme concentration was determined from its absorbance at 280 nm using a molar absorbance coefficient of 1.7 for 1 mg/ml hAChE [23] or 1.8 for 1 mg/ml hBChE [24] .
Crystallization of hBChE complexed with tacrine hBChE was crystallized using the hanging drop vapour diffusion method as described previously [22] . The mother liquor contained 1 mM tacrine and 0.1 M Mes (pH 6.5) and 2.1 M ammonium sulfate. A similar set-up was used to make crystals of the hBChEhuprine W complex, but failed to yield crystals large enough for diffraction analysis (shower of microcrystals). Crystals of the hBChE-tacrine complex grew in a couple of weeks at 20
• C. Crystals were then washed for a few seconds in a cryoprotectant solution (0.1 M Mes buffer, 1 mM tacrine, 2.3 M ammonium sulfate and 20 % glycerol) before being flash-cooled in liquid nitrogen for data collection.
Crystallization of hAChE complexed with FAS-2 and huprine W
Purified hAChE (0.1 mM, 6.5 mg/ml) was combined with FAS-2 (0.2 mM) and huprine W (1 mM) in 10 mM Hepes buffer, pH 7.4. The ternary complex was crystallized at a concentration of 0.1 mM, using the hanging drop method as described previously [25] . The mother liquor was 0.1 M Hepes buffer (pH 7.4) and 1.3 M ammonium sulfate. An equal amount of the protein and the mother liquor were mixed to yield a 3 μl drop. Crystals grew within a month at 10
• C. The crystals were transferred to a cryoprotectant solution (0.1 M Hepes buffer, pH 7.4, 1.6 M ammonium sulfate and 18 % glycerol) for few seconds before they were flash-cooled in liquid nitrogen.
X-ray data collection and processing, structure determination and refinement Diffraction data were collected at 100 K on the ID14-eh2 and ID14-eh4 beam-lines at the ESRF (European Synchrotron Radiation Facility). All datasets were processed with XDS (X-ray Detector Software) [26] , intensities of integrated reflections were scaled using XSCALE and structure factors were calculated using XDSCONV. The structures were solved with the CCP4 suite [27] using the recombinant hBChE structure (PDB code 1P0I) or the hAChE structure (PDB code 2X8B) as starting models. The initial models were refined by iterative cycles of model building with Coot [28] , then restrained and TLS refinement with Phenix [29] .
RESULTS
X-ray data and quaternary arrangement of hAChE
hAChE was co-inhibited by FAS-2 and huprine W in solution. The addition of FAS-2 was required to obtain diffracting crystals of the full-length form of hAChE. The co-crystals of the ternary complex were obtained under conditions identical to those used previously for hAChE-FAS-2 binary complexes [20, 25] . The crystals belong to space group H32 and diffract to 3.1 Å. The unit structure consists of three pairs of canonical hAChE dimers. Data and refinement statistics are shown in Table 1 .
The long C-terminal helix of the T-splice variants of cholinesterases contains the WAT (tryptophan amphiphilic tetramerization) sequence involved in a four-to-one association with one PRAD (proline-rich attachment domain) [30] . Yet, the WAT domain has never been observed in crystal structures of cholinesterases because it was either truncated by design [16, 22, 25, 31, 32] or no matching electron density was visible 
Figure 2 Crystal packing of hAChE in a complex with FAS-2 and huprine W
Three canonical dimers (red and green pairs) interact via extensive contacts between bound FAS-2 (yellow and magenta, surface shown) to form a non-physiological hexamer. The long C-terminal helices of each dimer cross at a 60 • angle and intertwine at the centre of the hexamer. Huprine W is represented as spheres (grey, carbon; blue, nitrogen; red, oxygen; green, chlorine). [20, 33] . In the structure shown in Figure 2 , we were fortunate to model six previously unreported turns of the WAT domain including residues 544-567. Although the side chains remain poorly resolved, the main chain was clearly identified. The C-terminal helices of the canonical dimers cross each other at Leu 546 , at a 60 • angle. This arrangement is difficult to reconcile with the X-ray structure of the four-to-one complex formed between an isolated portion of WAT and PRAD, where the helices run parallel to form a left-handed superhelix structure around an antiparallel left-handed PRAD helix [34] . In particular, the crossed helices do not allow the construction of a plausible tetramer model as that proposed by Dvir et al. [34] , thus strongly indicating that this arrangement is not representative of the conformation of the helices in the physiological tetramer. The three canonical dimers interact via FAS-2 molecules, forming a peculiar non-physiological hexamer with a central pore. The extremities of the C-terminal helices from each dimer are intertwined in the pore. A hexameric arrangement for the same recombinant hAChE (at high concentration) was observed by electron microscopy (G. Effantin, E. Carletti and J.P. Colletier, unpublished work).
Interactions of huprine W in the active site of hAChE A 7.5 σ peak in the initial F o -F c electron density was present in the active site of hAChE, which could be unambiguously modelled as the (7S,11S) configuration of huprine W (Figure 3, top panel) . Huprine W is stabilized in hAChE by interactions similar to those described for other huprine derivatives in complex with non-hAChE [36, 37] Additional stabilization of the quinolinium substructure is provided by a hydrogen bond between the aromatic nitrogen and the main chain carbonyl of His 447 (2.8 Å). Unlike in previous huprine-AChE complexes, the closest water molecule is at least 3.4 Å from the amino group, showing that this group does not interact strongly with the conserved water molecule network of the active site gorge. The water molecule network was well defined in the electron density map despite the low-resolution data. The hydroxyl group of huprine W makes strong hydrogen bonds with the γ -hydroxyl of Ser 203 and the α-amine of Gly 122 (2.3 and 2.9 Å). It occupies a similar position as that of the water molecule that often bridges the catalytic serine residue to the oxyanion hole in the apo forms of cholinesterases [38] .
X-ray structure of the tacrine-hBChE complex
The structure of tacrine-inhibited hBChE was solved at 2.1 Å resolution ( Table 1 ). The clear elongated peak near Trp 82 in the initial F o -F c electron density map reveals that tacrine binds to the catalytic site of hBChE in a very similar way to how huprines and tacrine bind to AChE [32, 37, 39] (Figure 3, An additional strong positive peak in the initial F o -F c electron density map is found in the vicinity of the catalytic serine residue (Figure 4) . A similar peak was first observed in the structure of recombinant hBChE crystallized in the absence of any ligand [40] . Careful analysis of the density in that case showed that it could be modelled as a carboxylic acid bound to Ser 198 with an unusually long bond distance of 2.16 Å between Ser 198 -Oγ and the carboxylic-C. The best density fit was achieved with a butyrate molecule. Very recently, a different recombinant hBChE expressed in insect cells, purified using a new protocol and crystallized under completely different conditions, displayed a similar carboxylic acid bound to the serine residue [41] . In that study, the density was modelled as a β-alanine rather than a butyrate. Assignment was on the basis of the observation that one terminal heavy atom was very close to a water molecule and thus more likely to be a hydrogen bond donor or acceptor. In the structure shown in Figure 4 , the shape of the density is not linear as was observed for the putative β-alanine or butyrate. Rather, it is consistent with a small cyclic molecule. After various attempts with substituted aromatic or saturated six-and fiveatom ring molecules, a remarkably good fit was obtained with formyl-proline (Figure 4 ). Yet, we stress that this interpretation remains a guess, especially knowing that the source of this putative molecule remains unknown (culture medium, protein degradation or bacterial contaminant?). The carboxylic carbon of the formylproline is not covalently bonded to the serine residue (2.9 Å). The serine residue adopts two alternative conformations. One oxygen atom is partly engaged in the oxyanion hole and makes strong hydrogen bonds with the Oγ of Ser 198 and the α-amine of Gly 117 (2.7 and 2.7 Å). In addition, the formyl oxygen is 2.9 Å from a water molecule connected to Thr 120 (2.7 Å). Weaker peaks of electron density close to Tyr 332 in the initial F o − F c electron density map were modelled as a string of dummy Obviously, this refinement model is speculative, but we believe that it is more satisfying to show these unidentified densities in the PDB model, especially when they are in regions as important as the active site.
DISCUSSION
Huprine substituents change the conformation of mammalian AChE
Since mAChE and hAChE share identical active site residues, a comparison of the complexes they form with different huprine derivatives provides insight into huprine specificities. Figure 5 (top panel) shows that the central three-ring scaffold of huprine in the mAChE structure is superimposable on the three rings of huprine W in the hAChE structure (RMSD = 0.3 Å). The presence of the triazole at position 9 vice ethoxyl in huprine W affects the conformation of Tyr 337 , Tyr 341 and Asp 74 ( Figure 5 , top panel, where the residue numbering for mAChE is the same as that for hAChE). In the hAChE-FAS-2-huprine W structure, Tyr 341 is hydrogen-bonded to Asp 74 , and Tyr 337 has sufficient room to point towards the hydroxyl of the ethoxyl substituent at position 9. In the mAChE structure [37] , Tyr 337 must rotate by 60
• clockwise away from the triazole substituent and towards Tyr 341 . In response, Tyr 341 rotates away around its Cα-Cβ bond by 90
• counterclockwise. The rotation of Tyr 341 is favoured by an aromatic stacking interaction with the triazole ring. However, the hydrogen bond between Tyr 341 and Asp 74 is lost. The loss of the hydrogen bond changes the orientation of Asp 74 , which pushes a nearby water molecule by 1.1 Å towards the amino group of huprine allowing the formation of a strong hydrogen bond (2.8 Å) in the mAChE structure. Thus the absence of an equivalent water hydrogen bond in the hAChE-huprine W structure seems related to the nature of the substituent at position 9. These conformation changes appear independent of the presence of FAS-2 because no rotation of Tyr 341 and subsequent loss of the hydrogen bond are observed in the structures of apo mAChE/hAChE and FAS2-mAChE/hAChE [16, 18, 31] .
From this analysis, it is apparent that the conformational adaptations of active site residues involved in the interaction with huprines are extremely difficult to predict from the apo structure alone. Because main chain translations occur, dedicated molecular docking software, even those implementing flexibility of the residue side chains, could not predict the various conformational changes induced by the binding of different huprines. The prediction of ligand binding to such a complex and flexible active site as that of hAChE necessitates a more elaborate strategy. Determination of the crystal structures for representative members of an inhibitor family seems to be a necessary first step in order to identify correctly the rules for active site and inhibitor interactions. To that end, we are examining the crystal structures of hAChE and hBChE bound to various inhibitors.
Once the basic rules of engagement are known, it should be possible to accurately dock other derivatives into the active site, either manually or by using docking software. Water molecules that are an integral part of the active site architecture would be conserved at this stage. Further refinement of the binding conformation then could be performed by means of molecular dynamics simulations. This phase would let the active site residues adapt their conformation to the specificities of each derivative. We described this strategy for huprine W binding to hAChE in an earlier report [21] . The process predicted the binding conformation and energy with remarkably accuracy, the RMSD between the predicted ligand co-ordinates and experimentally measured co-ordinates being only 0.4 Å. Top panel, huprine W-hAChE (cyan) and huprine triazole-mAChE (yellow). Bottom panel, huprine W-hAChE (cyan), huprine X-TcAChE (slate) and tacrine-hBChE (green). Key residues are represented by sticks with oxygen atoms in red, nitrogen atoms in dark blue, sulfur atoms in yellow and chlorine atoms in magenta. Conserved water molecules are represented as red spheres and chlorine atoms as magenta spheres. The van der Waals surface of the chlorine atom of huprine W and Met 447 -Cε of hBChE is represented as dots. Displayed residues and their numbering are strictly conserved for hAChE and mAChE.
Selectivity emerging from a hydrophobic pocket
Design of inhibitors that are selective for AChE from various organisms also requires a better understanding of the inhibitorprotein interactions than can be obtained by docking and molecular dynamics simulations alone. This point was described above by comparing the effect of substituting ethoxy by triazole on position 9 of huprine. Another example is provided by the analysis of the hydrophobic chlorine-binding subsite for huprines complexed with hAChE and TcAChE. Application of the insights obtained from hAChE and TcAChE can then be used to predict the consequences of the structure in that region on the binding of huprines to hBChE, DmAChE (Drosophila melanogaster AChE) and Culex pipens AChE.
The structures of hAChE in a complex with huprine W, TcAChE in a complex with huprine X and hBChE in a complex with tacrine are shown in Figure 5 ( Examination of the same region in hBChE reveals that the side chain of Met 437 fills the hydrophobic pocket. As shown in Figure 5 (bottom panel), the van der Waals volume of Met 437 -Cε (green dots) overlaps that of the chlorine atom of huprine W bound to hAChE (magenta dots). Thus the chlorine atom of huprine would not be able to fit into the active site of hBChE without a substantial rearrangement of the residues in the preferred hydrophobic chlorine-binding subsite. This steric restriction is reflected in the affinity of huprine W for hBChE (IC 50 = 1200 nM), where it binds three orders of magnitude more weakly than it does to hAChE (IC 50 = 1.1 nM) [21] . This strongly suggests that huprine W adopts a different orientation when bound to hBChE than when bound to hAChE. A similar trend is observed for the IC 50 of 6-chlorotacrine, which bears a chlorine atom at the same position as in huprine W (IC 50 = 8 nM for hAChE compared with IC 50 = 900 nM for hBChE) [42] .
By contrast, tacrine is a good fit for the hydrophobic region of hBChE with the closest atom of tacrine being 3.9 Å from Met 437 -Cε ( Figure 5, bottom panel) . This rationalizes why the inhibition constant of tacrine for hBChE is only 6-fold lower than that for TcAChE (K i = 25 nM for hBChE compared with K i = 3.8 nM for TcAChE) [43] .
Another aspect of the hydrophobic chlorine subsite is found when examining the structure of DmAChE [44] . In this enzyme, a channel exists connecting the active site gorge to the bulk solvent in the region of the hydrophobic chlorine-binding pocket. This channel results from the replacement of Tyr 449 in hAChE with an aspartate residue in the Drosophila enzyme. The X-ray structure of DmAChE in a complex with benzyl-tacrine (PDB code 1DX4) shows that position 6 of the tacrine moiety is next to this channel [32] . It follows that a large substituent at position 6 could avoid steric hindrance by entering into the channel of DmAChE, whereas it would not fit in the hydrophobic pocket of hAChE and would therefore reduce the binding affinity.
The same Tyr→Asp replacement is present in C. pipens AChE (UnitprotKB Q86GC8) and many other insect AChEs [45] . We propose that this feature could provide the basis on which to design specific inhibitors of insect AChE that would not interact significantly with hAChE.
Implications for the design of MTDLs
The X-ray structure reveals that huprine is closely embedded in the active site of hAChE. Although close embedding accounts for great affinity for the enzyme, it limits the number of positions available on the scaffold to introduce a linker for connecting a ligand for the second molecular target. In particular, any substitution on the central tricyclic substructure would lead to unfavourable steric clashes with active site residues. Substitution on the amine is an option that has been successfully employed, but at the price of disrupting the active site water network in the vicinity of the amine [19] . This is not an issue when the second ligand targets the peripheral site of the enzyme, because the synergy of binding to both sites is expected to largely counterbalance the unfavourable disruption of the water network [42] . However, this synergy does not exist for ligands that have no affinity for the peripheral site. Substitution at position 9 of huprine appears to be the best option as evidenced by the structure of huprine triazole [37] , because the linker can snake outside the gorge to the bulk solvent without disruption of the active site structure.
Despite the active site of hBChE being wider than that of hAChE, tacrine is also tightly embedded, with no apparent available substitution position that would be devoid of unfavourable steric effects. The huprine scaffold with substitution at position 9 appears again to be the best option for hBChEspecific MTDLs, under the condition to remove the chlorine substituent at position 3 for the reasons discussed above.
In summary, we presented structures of hAChE and hBChE in complexes with reversible inhibitors that are of interest for the design of MTDLs. Comparison of huprine complexes with mAChE, TcAChE and hAChE illustrates how active site gorge residues rearrange to better accommodate each derivative, and highlight the necessity of using full X-ray structure analysis to develop an accurate understanding of the protein structure changes that occur on binding, before attempting to make binding predictions via docking or molecular dynamics procedures. The structure of hBChE in a complex with tacrine re-enforces this conclusion.
